Extended Data Fig. 2: Percentages of immune cell subsets in tumor-bearing and naïve LyzM-Cre and LyzM-Cre RelF/F mice.
From: c-Rel is a myeloid checkpoint for cancer immunotherapy
a, Percentages of CD11b+Gr-1+ cells in the spleen of mice treated in Fig. 1f. n = 6 mice/group. b-d, Percentages of CD4+ cells in the spleen (b, n = 6/group), blood (c, n = 6/group), and tumor (d, n = 8/group) of mice treated in Fig. 1f. e-g, Percentages of CD4+CD25+ cells in the spleen (e, n = 6/group), blood (f, n = 6 for the LyzM-Cre group and n = 5 for the LyzM-Cre RelF/F group), and tumor (g, n = 3 for the LyzM-Cre group and n = 6 for the LyzM-Cre RelF/F group) of mice treated in Fig. 1f. h-j, Percentages of CD8+ cells in the spleen (h, n = 6/group), blood (i, n = 6/group), and tumor (j, n = 8/group) of mice treated in Fig. 1f. k-n, Percentages of the indicated leukocyte subsets in the tumor (n = 3 for the LyzM-Cre group and n = 6 for the LyzM-Cre RelF/F group) of mice treated in Fig. 1f (k, l), and the spleen (n = 3 for the LyzM-Cre group and n = 5 for the LyzM-Cre RelF/F group) of naïve mice (m, n). (***, P = 0.0002) Statistical significance was determined by two-tailed unpaired t-test (k). For all panels, data are presented as means ± s.e.m.
